Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.

Wern Yew DingAmeenathul Mazaya FawzyGiulio Francesco RomitiMarco ProiettiDaniele PastoriMenno V HuismanGregory Y H LipAmeenathul Mazaya Fawzynull null

Published in: Journal of thrombosis and thrombolysis (2023)

Keyphrases

cardiovascular events
phase ii
clinical trial
open label
coronary artery disease
atrial fibrillation
cardiovascular disease
phase iii
placebo controlled
double blind
adverse drug
randomized controlled trial
emergency department
type diabetes